Agentic AI-EnableD CardioVascular CAre TransfOrmation (ADVOCATE) Innovative Solutions Opening (ISO)

SOL #: ARPA-H-SOL-26-142Solicitation

Overview

Buyer

Health And Human Services
National Institutes Of Health
ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)
Washington, DC, 20005, United States

Place of Performance

Washington, DC

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

Health R&D Services; Health Care Services; Experimental Development (AN13)

Set Aside

No set aside specified

Timeline

1
Posted
Jan 12, 2026
2
Last Updated
Feb 23, 2026
3
Submission Deadline
Apr 1, 2026, 9:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Advanced Research Projects Agency for Health (ARPA-H) has issued the Agentic AI-Enabled CardioVascular CAre TransfOrmation (ADVOCATE) Innovative Solutions Opening (ISO), ARPA-H-SOL-26-142, seeking innovative solutions to modernize Cardiovascular Disease (CVD) care management. This program aims to develop a patient-facing autonomous agentic AI system for 24/7, scalable, safe, and effective cardiovascular care. An Amendment 01 was issued on February 5, 2026, modifying specific sections of the solicitation. Solution Summaries are due February 27, 2026, and Full Proposals are due April 1, 2026.

Scope of Work

The ADVOCATE program is structured into three Technical Areas (TAs) over a 39-month period:

  • TA1 (CVD Agent): Develop a clinically validated, regulatory-compliant, patient-facing AI agent for CVD care management, capable of diagnostic reasoning, treatment recommendations, and performing FDA-defined medical device functions.
  • TA2 (Supervisory Agent): Develop a disease-agnostic agent for continuous monitoring, auditability, and regulatory compliance of clinical agents, assessing risk, acuity, and accuracy.
  • TA3 (Scaled Implementation): Integrate CVD and Supervisory agents into healthcare settings, providing EHR data access, performing Scalability Studies, and evaluating cost-efficiency and safety. The program emphasizes collaboration between TA teams and with an IV&V partner.

Contract Details

  • Type: Multiple Other Transaction (OT) Agreements.
  • Period of Performance: 39 months, divided into Phase 1A (12 months), Phase 1B (12 months), and Phase 2 (15 months).
  • Set-Aside: None specified. Open to responsible sources including universities, non-profit organizations, small businesses, and other businesses. FFRDCs and government entities are prohibited as prime or sub-performers. Individuals providing contracted support to ARPA-H are ineligible due to Organizational Conflicts of Interest (OCI).
  • Place of Performance: Washington, DC.

Submission & Evaluation

Proposers must submit a solution summary followed by a full proposal via the ARPA-H Solution Submission Portal. Evaluation Criteria (descending order of importance):

  1. Overall Scientific and Technical Merit
  2. Proposer's Capabilities and/or Related Experience
  3. Potential Contribution to Relevance to the ARPA-H Mission and User Experience
  4. Assessment of Proposed Cost/Price

Key Deadlines

  • Solution Summary Due: February 27, 2026
  • Full Proposal Due: April 1, 2026

Amendment 01 Details (February 5, 2026)

  • Performer Collaboration Expectations (Section 1.2.5): Correction made to Table 7.
  • Proposing Teams (Section 5.1): Proposers for TA3 cannot submit for TA1 or TA2 in any capacity (prime, subperformer, multi-party team) and can only submit one TA3 proposal.
  • Organization Conflicts of Interest (OCI) (Section 6.2): Proposers are required to identify and disclose all facts relevant to any potential OCI involving themselves, their organization, and/or any proposed team member.

Required Attachments

Bidders must utilize specific templates for cost proposals:

  • Attachment 3a - ARPA-H Cost Proposal Spreadsheet - OTs: For proposals without Resource Sharing.
  • Attachment 3b - ARPA-H Cost Proposal Spreadsheet - OTs (Resource Sharing): For proposals involving Resource Sharing.
  • Attachment 3 - ARPA-H Cost Proposal Narrative: Outlines required format and content for cost justifications.
  • Attachment 2 - ARPA-H - OT Agreement Sample: Provides a sample of the Other Transaction Agreement terms, including critical clauses on Intellectual Property Rights and data management. Resource sharing is highly encouraged, with cash contributions preferred.

People

Points of Contact

SEE DESCRIPTION SECTIONPRIMARY

Files

Files

Download
Download
Download
Download
Download
Download

Versions

Version 3
Solicitation
Posted: Feb 23, 2026
View
Version 2Viewing
Solicitation
Posted: Feb 5, 2026
Version 1
Solicitation
Posted: Jan 12, 2026
View